Search results

Search for "multidrug resistance (MDR)" in Full Text gives 7 result(s) in Beilstein Journal of Nanotechnology.

Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy

  • Andreina Quevedo-Enríquez,
  • Katty Yi Zhang,
  • Denisse Yajaira Enriquez,
  • Byron Raul Inapanta,
  • Roxana Noemí Peroni and
  • Christian Rafael Quijia

Beilstein J. Nanotechnol. 2026, 17, 882–921, doi:10.3762/bjnano.17.64

Graphical Abstract
  • City of Buenos Aires, Argentina 10.3762/bjnano.17.64 Abstract Multidrug resistance (MDR) remains a major barrier to successful cancer chemotherapy, frequently resulting in therapeutic failure, tumor relapses, and poor clinical outcomes. Among the diverse mechanisms underlying MDR, the overexpression
  • . Keywords: cancer chemotherapy; efflux transporters; multidrug resistance (MDR); nanoparticles; siRNA nanocarriers; tumor-targeted therapy; Review 1 Introduction 1.1 Cancer and current challenges in chemotherapy Cancer remains one of the leading causes of mortality worldwide, with millions of new cases
  • compromised by multidrug resistance (MDR), a phenomenon in which cancer cells evade the cytotoxic effects of drugs through various mechanisms. Overexpression of efflux transporters, particularly P-glycoprotein (P-gp), is a well-documented contributor to this phenotype, although it is not the sole mechanism
PDF
Album
Review
Published 13 Jul 2026

Advances of aptamers in esophageal cancer diagnosis, treatment and drug delivery

  • Yang Fei,
  • Hui Xu,
  • Chunwei Zhang,
  • Jingjing Wang and
  • Yong Jin

Beilstein J. Nanotechnol. 2025, 16, 1734–1750, doi:10.3762/bjnano.16.121

Graphical Abstract
  • cancer cells, thereby significantly enhancing tumor-specific drug accumulation. Concurrently, siRNA-mediated silencing of MDR1 effectively suppresses P-gp-mediated drug efflux, overcoming multidrug resistance (MDR) in tumor cells. By integrating active targeting, gene silencing, and chemosensitization
PDF
Album
Review
Published 06 Oct 2025

Better together: biomimetic nanomedicines for high performance tumor therapy

  • Imran Shair Mohammad,
  • Gizem Kursunluoglu,
  • Anup Kumar Patel,
  • Hafiz Muhammad Ishaq,
  • Cansu Umran Tunc,
  • Dilek Kanarya,
  • Mubashar Rehman,
  • Omer Aydin and
  • Yin Lifang

Beilstein J. Nanotechnol. 2025, 16, 1246–1276, doi:10.3762/bjnano.16.92

Graphical Abstract
  • addition, the escalation of new glitches such as drug sensitivity in tumor cells has been reduced due to the emergence of multidrug resistance (MDR) by various factors, including ATP-dependent drug efflux, selective stress of drugs, altered DNA repair mechanisms, cellular heterogeneity, recurrence, and
PDF
Album
Review
Published 05 Aug 2025

Biocompatibility and cytotoxicity in vitro of surface-functionalized drug-loaded spinel ferrite nanoparticles

  • Sadaf Mushtaq,
  • Khuram Shahzad,
  • Tariq Saeed,
  • Anwar Ul-Hamid,
  • Bilal Haider Abbasi,
  • Nafees Ahmad,
  • Waqas Khalid,
  • Muhammad Atif,
  • Zulqurnain Ali and
  • Rashda Abbasi

Beilstein J. Nanotechnol. 2021, 12, 1339–1364, doi:10.3762/bjnano.12.99

Graphical Abstract
  • spheroid diameter and up to 74 ± 8.9% of cell death after two weeks. In addition, they also inhibited multidrug resistance (MDR) pump activity in both cell lines suggesting effectivity in MDR cancers. Among the tested MFe2O4 NPs, CFO nanocarriers were the most favorable for targeted cancer therapy due to
PDF
Album
Full Research Paper
Published 02 Dec 2021

Tight junction between endothelial cells: the interaction between nanoparticles and blood vessels

  • Yue Zhang and
  • Wan-Xi Yang

Beilstein J. Nanotechnol. 2016, 7, 675–684, doi:10.3762/bjnano.7.60

Graphical Abstract
  • defeat some of the drawbacks in traditional cancer chemotherapy (such as multidrug resistance (MDR) in tumors [6]). They can be modified to enhance the specificity of tumor therapy. Admittedly, no scientist could ignore its prominent latent prospect, but meanwhile numerous researches show their concerns
PDF
Album
Review
Published 06 May 2016

PLGA nanoparticles as a platform for vitamin D-based cancer therapy

  • Maria J. Ramalho,
  • Joana A. Loureiro,
  • Bárbara Gomes,
  • Manuela F. Frasco,
  • Manuel A. N. Coelho and
  • M. Carmo Pereira

Beilstein J. Nanotechnol. 2015, 6, 1306–1318, doi:10.3762/bjnano.6.135

Graphical Abstract
  • polymeric NPs will increase bioavailability by preventing drug degradation before administration, increasing the half-life of vitamin D3 in the bloodstream, avoiding the first-pass effect and circumventing the multidrug resistance (MDR) problem [18]. Also it is well documented that PLGA NPs are efficiently
PDF
Album
Supp Info
Full Research Paper
Published 12 Jun 2015

Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating

  • Tingjun Lei,
  • Alicia Fernandez-Fernandez,
  • Romila Manchanda,
  • Yen-Chih Huang and
  • Anthony J. McGoron

Beilstein J. Nanotechnol. 2014, 5, 313–322, doi:10.3762/bjnano.5.35

Graphical Abstract
  • and protect their cargo from degradation, including drugs and other types of biomolecules [1][2]. NPs have also proven to be useful in overcoming multidrug resistance (MDR) by preventing the direct interaction of drug exporter pumps with their substrates once encapsulated in NPs [3]. An additional
PDF
Album
Supp Info
Full Research Paper
Published 18 Mar 2014
Other Beilstein-Institut Open Science Activities